Xolair Roundtable: Three US doctors react to UK restrictions
A few months ago, we noticed news from England that Britain’s national health service (NHS) rejected use of Xolair for after the National Institute for Clinical Excellence (NICE) said it was too...
View ArticleThe High Cost of Treating Severe Asthma
By Dr. Paul Ehrlich Great timing. An article on the front page of the Sunday New York Times on colonoscopies happened to coincide with the fact that I finally received an answer to a question eight...
View ArticleXolair Roundtable: Three US doctors react to UK restrictions
A few months ago, we noticed news from England that Britain’s national health service (NHS) rejected use of Xolair for after the National Institute for Clinical Excellence (NICE) said it was too...
View ArticleThe High Cost of Treating Severe Asthma
By Dr. Paul Ehrlich Great timing. An article on the front page of the Sunday New York Times on colonoscopies happened to coincide with the fact that I finally received an answer to a question eight...
View ArticleChronic Urticaria: the Omalizumab (Xolair) Difference
By Dr. Paul Ehrlich Back when we wrote our book Asthma Allergies Children: a parent’s guide, Dr. Chiaramonte and I both expressed our exasperation over the dismal state of treatment for chronic...
View ArticleMonoclonal Antibodies—An allergist perspective on the new biologics
Interview with Dr. Purvi Parikh Last week we published our latest piece on dupilumab (Dupixent). But this is just one of several biologic “miracle” drug that have found their way into the allergist...
View Article
